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therapy, they had their biomarkers evaluated. Identifica-
tion of silent cardiac TOD was done by transthoracic
echocardiography, stress echocardiography, and/or myo-
cardial perfusion imaging. Carotid–femoral pulse wave
velocity.
Results: Results showed that 96 (35%) patients had
evidence of cTOD. Left ventricular hypertrophy evalu-
ated by LV mass index showed the highest prevalence
(32.7%), followed by left ventricular diastolic dysfunction
(28.9%), left atrial enlargement (19.1%), systolic dysfunc-
tion (10.6%), ischemia (7.1%) and the lowest was PWV
(2.7%). The discrimination power as evaluated by area
under the curve [AUC] for BNP to identify any form of
silent cTOD was 0.79 overall and 0.83 in men, while for
hs-cTnT it was 0.70 and 0.74 in women. The combined
AUC for BNP and hs-cTnT together was 0.81 and 0.82
in men. Week discrimination power existed for of other
biomarkers, with AUCs of 0.61 for microalbuminuria,,
0.60 for hs-CRP, and 0.58 for eGFR.
Conclusions: Asymptomatic patients treated for pri-
mary prevention, existing silent cTOD could be identified
by BNP screening. The results of hs-cTnT was weaker
than that of BNP. Combining BNP plus hs-cTnT together
showed best results. Primary prevention could be
improved by Prescreening with BNP ± cTnT followed
by phenotyping.
http://dx.doi:10.1016/j.jsha.2013.03.177
Effect of circadian rhythm of blood pressure on
arterial wall stiffness and on left ventricular dia-
stolic dysfunction
Yahia M. Elrakshy, Akram M. Fayed, Mahmood M.
Hassanein
Background: Arterial stiffness is a risk factor for car-
diovascular morbidity and mortality. Variability of blood
pressure has been reported to be related to worse cardio-
vascular outcome. The relationship between the arterial
stiffness and the circadian rhythm of blood pressure (BP)
has been controversial. The objective was to the examine
impacts of BP variability on left ventricular diastolic func-
tion and arterial stiffness in the hypertensive patients.
Methods: Ambulatory BP monitoring, pulse wave
velocity, and echocardiography were performed in 268
patients (153 males, 47 ± 11 years) with HTN and
pre-HTN. BP was measured at the outpatient clinic and
24-h ABPM was performed. Using carotid femoral appla-
nation tonometry, PWA was performed for evaluation of
systemic arterial stiffness expressed as augmentation
index. Echocardiograms were performed and an average
of 3–6 cardiac cycles was done for all measurements
including the left ventricular mass index (LVMI), relative
wall thickness (RWT), trans mitral flow propagation
velocity (Vp), TDI, and midwall shortening fraction
(MWSF). Nocturnal dipping was defined as a reduction
of diastolic BP (DBP) by >10% of systolic BP (SBP) when
compared with the daytime values. Isolated systolic non-
dipping, is reduction of <10% in the SBP, When com-
pared with the daytime values. Isolated diastolic non-
dipping is reduction of <10% in the DBP. Both systolic
and diastolic non-dipping is reduction of <10% in both
SBP and DBP.
Results: Among groups, the clinic SBP and DBP,
daytime mean BP of 24-h ABPM, gender and body mass
index were not statistically different. Augmentation pres-
sure (AP), augmentation index (AI) showed statistically
significant difference (p = 0.008 and 0.021, respectively).
Multivariate analysis showed that isolated diastolic
non-dipping was correlated with arterial stiffness
expressed as AI only in young group.
http://dx.doi:10.1016/j.jsha.2013.03.178
Feasibility of using ivabridine in adult congenital
heart disease patients
Zakariya Albinmousa, Khalid Alnajashi,
Khalid Dagriri, Ahmed Alfagih, Saleh Alghamdi
Background: Beta Blockers have been the main
agent to control the heart rate in Fontan patients. Ivabri-
dine which is a selective SA node inhibitor has been used
in adult cardiac patient with successful result in control-
ling heart rate for those who did not respond to beta
blockers alone. This agent has not been reported to be
used in adult congenital heart disease patients.
Objective: To determine the feasibility of using iva-
bridine in patient with adult congenital heart disease and
inappropriate sinus tachycardia who failed to respond to
beta blockers.
Methods: 3 patients all with single ventricle physiol-
ogy were on maximum tolerable dose of Beta Blockers,
with inappropriate sinus tachycardia started on ivabri-
dine. Average follow up was 52 weeks with regular holter
monitor. Pro-BNP, 6 min walk test, and echocardiogra-
phy at baseline and 24 weeks of follow up. Physical exam-
ination and interrogation for any detected side effect was
done on each visit.
Result: At baseline the average heart rate was 100 ± 4
BPM, ivabridine started on with target dose 7.5 mg BD.
The mean average heart rate at 12 weeks was 83 BPM,
78 BPM on 24 weeks, and 85 BPM on 52 weeks. There
was no reported side effect by the patients or an effect
on single ventricle function.
Conclusion: ivabridine can be used in single ventri-
cle patients to reduce the heart rate in conjunction with
beta blockers. However larger study is needed to assess
its isolated long term effect on a diseased sinus node.
http://dx.doi:10.1016/j.jsha.2013.03.179
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Familial dilated cardiomyopathy (DCM) is genetically
heterogeneous. Mutations in more than 30 genes have
been identified in familial cases; mostly inherited as
autosomal dominant. Defective genes in isolated reces-
sive DCM are rarely observed. Recently, heterozygous
mutations in NEXN gene, which encodes a cardiac Z-disc
protein, have been identified in patients with dominantly
inherited dilated and hypertrophic forms of cardiomyop-
athy. Through our Cardiovascular Genetics Program, we
have conducted genome-wide analysis in 43 consanguin-
eous Saudi families with recessive forms of cardiomyop-
athy. The analysis detected a region of homozygosity
(ROH) on chromosome 1p31 in one family who has two
affected infants with severe DCM. The index case pre-
sented at the age of 1 month with severely dilated left
ventricle with ejection fraction of 21%. The identified
ROH in this family was found to be shared by the 2
affected siblings and was not found in their parents
and unaffected sibling. Direct sequencing of 6 candidate
genes within the identified ROH revealed a novel homo-
zygous deletion (c.1582-1584delGAA) in NEXN gene in
both affected siblings. This mutation leads to a deletion
of glutamate, at position 528, which is a highly conserved
amino acid. To our knowledge, this is the first study iden-
tifying a homozygous mutation in NEXN gene in associ-
ation with recessive cardiomyaopthy. This finding could
be utilized to prevent the recurrence of DCM through
preimplantation genetic diagnosis and carrier screening
for at-risk family members. Our work also illustrates
the importance of homozygosity analysis in identifying
genetic causes of familial cardiovascular disorders in
our highly consanguineous population.
http://dx.doi:10.1016/j.jsha.2013.03.180
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